New Drug Doubles Time In Patients With Pancreatic Cancer
In a clinical trial, researchers found that a drug called Daraxonrasib doubled the survival time in patients diagnosed with pancreatic cancer. This is significant as more than half of people with pancreatic cancer die within three months of diagnosis. Amid this, a report projected a shortfall of 100 million cancer care workers by 2050.
Trending Videos
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)